David Pyrce, M.B.A.

SVP, Innovation & Chief Commercial Officer, Investor Relations

Mr. Pyrce joined Nantkwest in 2015 as its Senior Vice President of Innovation & CCO where he leads Investor Relations, drives R&D innovation and translates it into high-impact commercial immunotherapies. Mr. Pyrce brings more than 25 years of biotechnology and healthcare industry operating experience as a founder, CEO, business development, marketing & sales executive with a passion for creating and growing game-changing organizations with laser focus on bringing the promise of 21st century medicine to cancer patients today through the discovery and development of novel, high impact cancer immunotherapies. Prior to joining NantKwest, Mr. Pyrce was the Senior Vice President of Strategic Initiatives at NantHealth focusing on the development and commercial launching of GPS Cancer, the world’s first whole genome, transcriptome and quantitative proteomics molecular diagnostic test. Prior to the joining the NantWorks, LLC., Mr. Pyrce was the founder and CEO of Genomic Principles, a comprehensive, multi-omics molecular diagnostic firm dedicated to applying genomic sequencing data into patient-specific, neoantigen-based cancer vaccines. Mr. Pyrce completed the Advanced Executive Management program at Northwestern, has an MBA from the Stuart School at the Illinois Institute of Technology, and dual Bachelor of Science degrees in Chemistry and Biology from Northern Illinois University.

Patrick Soon-Shiong,

Barry J. Simon, M.D.

Leonard S. Sender, M.D.

John H. Lee, M.D., F.A.C.S,

Hans G. Klingemann, M.D., Ph.D.

Steven Yang, J.D.

Sonja Nelson

David Pyrce, M.B.A.